Feature | April 07, 2015

Leading Cardiovascular Societies Release New Guidance on Use of Heart Pumps

Expert consensus statement addresses expanding options for percutaneous mechanical support devices

expert consensus, SCAI, ACC, HFSA, STS, heart pumps, MCS devices

The Abiomed Impella device

April 7, 2015 — An expert consensus statement released by four leading cardiovascular societies provides new guidance on percutaneous mechanical circulatory support (MCS) devices for treatment of heart failure. The statement — jointly released by the Society for Cardiovascular Angiography and Interventions (SCAI), American College of Cardiology (ACC), Heart Failure Society of America (HFSA) and The Society of Thoracic Surgeons (STS) —aims to help physicians match the right device with the right patient.

The statement has been endorsed by the American Heart Association (AHA), Cardiological Society of India (CSI) and the Latin American Society of Interventional Cardiology (SOLACI). The Canadian Association of Interventional Cardiology (CAIC) has affirmed the value of the statement.

Greater availability of percutaneous MCS devices for treatment of heart failure is helping expand treatment options for a rapidly growing number of acutely and chronically ill cardiac patients who could benefit from the devices.

“Percutaneous mechanical circulatory support is revolutionizing the treatment of high-risk cardiac patients,” said Charanjit S. Rihal, M.D., FSCAI, FACC, chair of the Division of Cardiovascular Diseases at the Mayo Clinic, Rochester, Minn., and lead author of the paper. “In certain patients, these devices can mean the difference between recovery and the need for heart transplant or death, and they may be used to maintain hemodynamic stability during interventional procedures and as a bridge to longer-term treatment. The new consensus statement will help physicians select devices for the patients who are most likely to benefit.”

To develop the new recommendations, a panel of experts reviewed scientific data on all of the available devices, including intraaortic balloon pumps (IABP), left atrial to aorta assist devices (TandemHeart), left ventricle to aorta assist devices (Impella), extracorporeal membrane oxygenation (ECMO) as well as methods for right-sided heart support. The expert panel also reviewed indications for percutaneous MCS, including complications of heart attack, high-risk angioplasty and stenting (also known as percutaneous coronary intervention, or PCI), and advanced heart failure and cardiogenic shock.

Based on the available data and anticipated benefits and risks, the panel determined percutaneous MCS provides superior circulatory support compared to medical therapy, especially when using left ventricular assist devices. Early placement of MCS can benefit patients in cardiogenic shock when initial interventions fail to stabilize the patient. MCS may also benefit high-risk PCI patients and certain patients with acute decompensated heart failure whose symptoms are worsening despite treatment. MCS may also be used in patients who failed to wean off a heart-lung bypass machine. The evidence does not support routine use of MCS in heart attack patients.  

“MCS utilization is clearly increasing, and this document should assist clinicians in recognizing when early support is needed, and what that support should look like,” said Srihari S. Naidu, M.D., FSCAI, FACC, FAHA, director of the cardiac cath lab at Winthrop University Hospital and vice chair of the consensus document’s writing committee.

The expert consensus statement also highlights emerging treatment opportunities, such as for patients undergoing percutaneous valve replacement who have severe, non-operable valve disease, and some patients undergoing electrophysiological procedures. Currently, most percutaneous MCS devices cannot be used in children due to size limitations, but the authors note this is an important area for future development. Registries and randomized controlled trials are also critically needed to compare different devices and treatment strategies across patient populations.

The paper, titled “SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Cardiac Assist Devices in Cardiovascular Care,” is co-published in Catheterization and Cardiovascular Interventions, the Journal of the American College of Cardiology and the Journal of Cardiac Failure. 

For more information: www.scai.org, www.acc.org, www.hfsa.org, www.sts.org

Related Content

American College of Cardiology Expands Patient Navigator Program
News | Cath Lab | March 21, 2018
March 21, 2018 — Hundreds of hospitals across the United States will have access to tools and resources to help impro
Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init